{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:16:21Z","timestamp":1793085381256,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"CrusoeNET"},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>An explorative ancillary study of the French CrusoeNET cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced\/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS, and\/or elevation of urinary 5-HIAA (u5HIAA) twice greater than the upper limit of normal. All patients included had 1 available serum stored within the local biobank between January 2021 and April 2022. Echocardiography was performed by 1 of the 3 expert cardiologists of the Lyon-EURACAN-CoE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 138 patients with NETs, mainly of the small intestine and lung, and 19 of them had a CHD. Analysis showed that s5HIAA was well correlated with u5HIAA (\u03c1 = 0.824 [0.76-0.88], P &amp;lt; .0001) and was a good biomarker for CHD detection (receiver operating characteristic curve = 0.85 [0.75-0.94], P &amp;lt; .0001). Using a threshold value of 757\u2005nmol\/L, the sensitivity and specificity for the detection of CHD were 84% and 80%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>s5HIAA is highly sensitive and specific for CHD detection. It could be used as a pre-screening tool in centres where systematic and regular echocardiography by an expert cardiologist is not performed in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae150","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:57:39Z","timestamp":1732733859000},"page":"570-578","source":"Crossref","is-referenced-by-count":5,"title":["Serum and urinary 5-hydroxyindolacetic acid, serotonin, chromogranin A, and NT-proBNP for the detection of carcinoid heart disease"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0127-6944","authenticated-orcid":false,"given":"Antoine","family":"Lecoeur","sequence":"first","affiliation":[{"name":"Service d\u2019Oncologie M\u00e9dicale, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita-Maria","family":"Sfeir","sequence":"additional","affiliation":[{"name":"Service de Biochimie et biologie mol\u00e9culaire, Hospices Civils de Lyon , Bron 69500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gerard","sequence":"additional","affiliation":[{"name":"Service d\u2019Oncologie M\u00e9dicale, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Souifi","sequence":"additional","affiliation":[{"name":"Service de Biochimie et biologie mol\u00e9culaire, Hospices Civils de Lyon , Bron 69500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Damour","sequence":"additional","affiliation":[{"name":"Service de Biochimie et biologie mol\u00e9culaire, Hospices Civils de Lyon , Bron 69500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3896-4588","authenticated-orcid":false,"given":"Catherine","family":"Lombard-Bohas","sequence":"additional","affiliation":[{"name":"Service d\u2019Oncologie M\u00e9dicale, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Francois","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Fort","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Delsart","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Forestier","sequence":"additional","affiliation":[{"name":"Service d\u2019Oncologie M\u00e9dicale, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-4561","authenticated-orcid":false,"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[{"name":"Service d\u2019Oncologie M\u00e9dicale, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]},{"name":"Gastroenterology and Technologies for Health, Centre de Canc\u00e9rologie de Lyon, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard , Lyon 69008 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Durand","sequence":"additional","affiliation":[{"name":"Service d\u2019Oncologie M\u00e9dicale, Hospices Civils de Lyon, Centre d\u2019Excellence ENETS , Lyon 69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3462-4239","authenticated-orcid":false,"given":"Laurence","family":"Chardon","sequence":"additional","affiliation":[{"name":"Service de Biochimie et biologie mol\u00e9culaire, Hospices Civils de Lyon , Bron 69500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"10","key":"2024122416520003400_lvae150-B1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"2024122416520003400_lvae150-B2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024122416520003400_lvae150-B3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.dld.2020.02.011","article-title":"Digestive neuroendocrine neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","volume":"52","author":"de Mestier","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"7","key":"2024122416520003400_lvae150-B4","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"2024122416520003400_lvae150-B5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1159\/000518651","article-title":"Clinical features and prognosis of patients with carcinoid syndrome and carcinoid heart disease: a retrospective multicentric study of 276 patients","volume":"112","author":"Fijalkowski","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2024122416520003400_lvae150-B6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.amjsurg.2022.03.054","article-title":"The prevalence, operations, and outcomes of carcinoid heart disease","volume":"224","author":"Macfie","year":"2022","journal-title":"Am J Surg"},{"issue":"10","key":"2024122416520003400_lvae150-B7","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors. An expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2024122416520003400_lvae150-B8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u2014\u2018something in the way it moves","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"21","key":"2024122416520003400_lvae150-B9","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1161\/CIRCULATIONAHA.105.553750","article-title":"Prognosis of carcinoid heart disease: analysis of 200 cases over two decades","volume":"112","author":"M\u00f8ller","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"2024122416520003400_lvae150-B10","doi-asserted-by":"publisher","first-page":"e13199","DOI":"10.1111\/jne.13199","article-title":"Four decades of experience with carcinoid heart disease: an analysis of 84 patients","volume":"34","author":"Levy","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"2024122416520003400_lvae150-B11","doi-asserted-by":"publisher","first-page":"e1673","DOI":"10.1210\/clinem\/dgaa924","article-title":"Plasmatic and urinary 5-hydroxyindolacetic acid measurements in patients with midgut neuroendocrine tumors: a GTE study","volume":"106","author":"de Mestier","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024122416520003400_lvae150-B12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.amjcard.2008.05.047","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume":"102","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"issue":"26","key":"2024122416520003400_lvae150-B13","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2008.18.7047","article-title":"Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor","volume":"27","author":"Korse","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024122416520003400_lvae150-B14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa021451","article-title":"Factors associated with progression of carcinoid heart disease","volume":"348","author":"M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2024122416520003400_lvae150-B15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/00365513.2023.2286645","article-title":"Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumours","volume":"83","author":"Ewang-Emukowhate","year":"2023","journal-title":"Scand J Clin Lab Invest"},{"issue":"5","key":"2024122416520003400_lvae150-B16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0004563215613109","article-title":"Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement","volume":"53","author":"Adaway","year":"2016","journal-title":"Ann Clin Biochem"},{"issue":"3","key":"2024122416520003400_lvae150-B17","doi-asserted-by":"publisher","first-page":"e13060","DOI":"10.1111\/jne.13060","article-title":"Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force)","volume":"34","author":"Hofland","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"10","key":"2024122416520003400_lvae150-B18","doi-asserted-by":"publisher","first-page":"e13327","DOI":"10.1111\/jne.13327","article-title":"The role of N-terminal pro-brain natriuretic peptide, chromogranin A, and 5-hydroxyindoleacetic acid in screening for carcinoid heart disease","volume":"35","author":"Johnson","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2024122416520003400_lvae150-B19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cca.2013.10.025","article-title":"Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker","volume":"428","author":"Tohmola","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"4","key":"2024122416520003400_lvae150-B20","doi-asserted-by":"publisher","first-page":"e13096","DOI":"10.1111\/jne.13096","article-title":"Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours","volume":"34","author":"Meyer","year":"2022","journal-title":"J Neuroendocrinol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae150\/60834499\/lvae150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/6\/570\/60930058\/lvae150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/6\/570\/60930058\/lvae150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T16:52:10Z","timestamp":1735059130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/191\/6\/570\/7909570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae150","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,11,27]]}}}